Shenzhen Capchem Technology (300037) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
6 Jun, 2025Executive summary
Revenue for Q1 2025 reached RMB 2.00 billion, up 32.14% year-over-year, with net profit attributable to shareholders at RMB 229.88 million, a 39.30% increase year-over-year.
Basic EPS was RMB 0.31, up 40.91% year-over-year; diluted EPS was RMB 0.32, up 52.38% year-over-year.
Operating cash flow improved but remained negative at -RMB 286.23 million, a 28.81% improvement year-over-year.
Financial highlights
Gross margin improved as revenue growth outpaced cost increases; operating profit rose 43.79% year-over-year to RMB 269.82 million.
Net profit margin increased, with net profit at RMB 231.50 million, up 41.93% year-over-year.
Total assets at quarter-end were RMB 17.59 billion, down 0.21% from year-end 2024; equity attributable to shareholders rose 2.48% to RMB 9.99 billion.
Non-recurring gains totaled RMB 7.99 million, mainly from government subsidies and investment returns.
Outlook and guidance
2024 annual profit distribution plan approved: cash dividend of RMB 4 per 10 shares (pre-tax), no bonus shares or capital increase.
Convertible bond (宙邦转债) remains outstanding with no conversions in Q1 2025; latest conversion price is RMB 41.98 per share.
Latest events from Shenzhen Capchem Technology
- Q1 2026 saw revenue up 67.85% and net profit up 109.02% year-over-year.300037
Q1 202628 Apr 2026 - Revenue up 4.85%, net profit down 6.83%, strong global expansion and R&D investment.300037
Q4 202426 Dec 2025 - Q3 2025 revenue up 13.6%, net profit down 7.5%, with strong cash flow and higher R&D spend.300037
Q3 202529 Oct 2025 - H1 2025 revenue up 18.58%, net profit up 16.36%, with strong growth across all segments.300037
Q2 202526 Aug 2025 - YTD net profit fell 12% and operating cash flow turned sharply negative.300037
Q3 202413 Jun 2025 - Revenue up 4.35% but net profit down 19.54% as margin pressure persists; global expansion continues.300037
Q2 202413 Jun 2025